Aldeyra Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this annual report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized, in the Commonwealth of Massachusetts, on March 7, 2024.
| ALDEYRA THERAPEUTICS, INC. | |
|---|---|
| By: | /s/ Todd C. Brady, M.D., Ph.D. |
| Todd C. Brady, M.D., Ph.D. | |
| President and Chief Executive Officer | |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Todd C. Brady and Bruce Greenberg, and each of them, as his or her true and lawful attorneys-in-fact, proxies, and agents, each with full power of substitution, for him in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact, proxies, and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, proxies, and agents, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1934, this annual report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Todd C. Brady, M.D., Ph.D. | Chief Executive Officer and Director | March 7, 2024 |
| Todd C. Brady, M.D., Ph.D. | (principal executive officer) | |
| /s/ Bruce Greenberg | Senior Vice President of Finance, Interim Chief Financial Officer | March 7, 2024 |
| Bruce Greenberg | (principal financial and accounting officer) | |
| /s/ Richard H. Douglas, Ph. D. | Chairman of the Board of Directors | March 7, 2024 |
| Richard H. Douglas, Ph.D. | ||
| /s/ Ben Bronstein, M.D. | Director | March 7, 2024 |
| Ben Bronstein, M.D. | ||
| /s/ Martin J. Joyce | Director | March 7, 2024 |
| Martin J. Joyce | ||
| /s/ Nancy Miller-Rich | Director | March 7, 2024 |
| Nancy Miller-Rich | ||
| /s/ Gary Phillips, M.D. | Director | March 7, 2024 |
| Gary Phillips, M.D. | ||
| /s/ Neal Walker, D.O. | Director | March 7, 2024 |
| Neal Walker, D.O. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.